Minocycline and TBI

7 Potential Neuroprotective Strategies for Traumatic Brain Injury 

Fenofibrate (propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate), a fibric acid derivative (Fig. 7.6), mainly exerts its effect via the activation of speciflc nuclear receptor called peroxisome proliferator-activated receptor alpha (PPARa). This PPARa agonist is primarily used to decrease the cholesterol levels in cardiovascular diseases patients. Like statins, fenofibrate also reduces triglycerides and low- and very low density protein levels. It also increases high-density lipoprotein levels in the body. Fenofibrate also has nonlipid (i.e., pleiotropic) effects (reduction in fibrinogen, C-reactive protein, and uric acid levels and improvement in the flow-mediated dilatation). 

Fenofibrate also reduces TBI-mediated neurological deficits, the edema, and the cerebral lesion (Chen et al., 2007). Fenofibrate promotes neurological recovery by exerting anti-inflammatory effect as evidenced by downregulation in 

Rosiglitazone (RSG) (Fig. 7.6) is another PPARy agonist that has been used to reduce inflammation and provide neuroprotection in experimental models of ischemia, intracerebral hemorrhage, and surgical brain injury (SBI) (Hyong et al., 2008). SBI can cause postoperative complications such as brain edema after 

---